Cargando…

Psoralidin inhibits osteosarcoma growth and metastasis by downregulating ITGB1 expression via the FAK and PI3K/Akt signaling pathways

BACKGROUND: Psoralea corylifolia is a medicinal leguminous plant that has long been used to treat various diseases. Psoralidin (PSO) is the main extract compound of P. corylifolia and exhibits antibacterial, antitumor, anti-inflammatory, antioxidant, and other pharmacological activities. PSO has dem...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Shengwen, Liu, Senrui, Chen, Bowen, Du, Chengcheng, Xiao, Pengcheng, Luo, Xuefeng, Wei, Li, Lei, Yiting, Zhao, Chen, Huang, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10064721/
https://www.ncbi.nlm.nih.gov/pubmed/37004120
http://dx.doi.org/10.1186/s13020-023-00740-w
_version_ 1785017957658656768
author Cheng, Shengwen
Liu, Senrui
Chen, Bowen
Du, Chengcheng
Xiao, Pengcheng
Luo, Xuefeng
Wei, Li
Lei, Yiting
Zhao, Chen
Huang, Wei
author_facet Cheng, Shengwen
Liu, Senrui
Chen, Bowen
Du, Chengcheng
Xiao, Pengcheng
Luo, Xuefeng
Wei, Li
Lei, Yiting
Zhao, Chen
Huang, Wei
author_sort Cheng, Shengwen
collection PubMed
description BACKGROUND: Psoralea corylifolia is a medicinal leguminous plant that has long been used to treat various diseases. Psoralidin (PSO) is the main extract compound of P. corylifolia and exhibits antibacterial, antitumor, anti-inflammatory, antioxidant, and other pharmacological activities. PSO has demonstrated inhibitory effects in several cancers; however, its inhibitory effect on osteosarcoma has not been reported. This study aimed to evaluate the inhibitory effect of PSO on osteosarcoma and elucidate the underlying molecular mechanisms. METHODS: Crystal violet, cell counting kit-8 (CCK8), and 5-Ethynyl-2′-deoxyuridine (EdU) staining assays were used to assess the inhibitory effect of PSO on the proliferation of 143B and MG63 osteosarcoma cells. Wound healing and Transwell assays were conducted to evaluate the effects of PSO on osteosarcoma cell migration and invasion. The cell cycle and apoptosis were analyzed using flow cytometry. To determine the possible molecular mechanisms, RNA-sequencing was performed and protein expression was analyzed by western blotting. The inhibitory effect of PSO on osteosarcoma in vivo was analyzed using a mouse model of orthotopic osteosarcoma and immunohistochemistry. RESULTS: PSO inhibited osteosarcoma cell proliferation in a concentration-dependent manner, inhibited cell migration and invasion, and induced cell-cycle arrest and apoptosis. Mechanistically, PSO treatment significantly inhibited the focal adhesion kinase (FAK) and phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathways by downregulating ITGB1 expression in both MG63 and 143B cells. Furthermore, we demonstrated that PSO restrained osteosarcoma growth in vivo. CONCLUSION: PSO may suppress osteosarcoma via the FAK and PI3K/Akt signaling pathways by downregulating ITGB1 expression. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13020-023-00740-w.
format Online
Article
Text
id pubmed-10064721
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-100647212023-04-01 Psoralidin inhibits osteosarcoma growth and metastasis by downregulating ITGB1 expression via the FAK and PI3K/Akt signaling pathways Cheng, Shengwen Liu, Senrui Chen, Bowen Du, Chengcheng Xiao, Pengcheng Luo, Xuefeng Wei, Li Lei, Yiting Zhao, Chen Huang, Wei Chin Med Research BACKGROUND: Psoralea corylifolia is a medicinal leguminous plant that has long been used to treat various diseases. Psoralidin (PSO) is the main extract compound of P. corylifolia and exhibits antibacterial, antitumor, anti-inflammatory, antioxidant, and other pharmacological activities. PSO has demonstrated inhibitory effects in several cancers; however, its inhibitory effect on osteosarcoma has not been reported. This study aimed to evaluate the inhibitory effect of PSO on osteosarcoma and elucidate the underlying molecular mechanisms. METHODS: Crystal violet, cell counting kit-8 (CCK8), and 5-Ethynyl-2′-deoxyuridine (EdU) staining assays were used to assess the inhibitory effect of PSO on the proliferation of 143B and MG63 osteosarcoma cells. Wound healing and Transwell assays were conducted to evaluate the effects of PSO on osteosarcoma cell migration and invasion. The cell cycle and apoptosis were analyzed using flow cytometry. To determine the possible molecular mechanisms, RNA-sequencing was performed and protein expression was analyzed by western blotting. The inhibitory effect of PSO on osteosarcoma in vivo was analyzed using a mouse model of orthotopic osteosarcoma and immunohistochemistry. RESULTS: PSO inhibited osteosarcoma cell proliferation in a concentration-dependent manner, inhibited cell migration and invasion, and induced cell-cycle arrest and apoptosis. Mechanistically, PSO treatment significantly inhibited the focal adhesion kinase (FAK) and phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathways by downregulating ITGB1 expression in both MG63 and 143B cells. Furthermore, we demonstrated that PSO restrained osteosarcoma growth in vivo. CONCLUSION: PSO may suppress osteosarcoma via the FAK and PI3K/Akt signaling pathways by downregulating ITGB1 expression. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13020-023-00740-w. BioMed Central 2023-03-31 /pmc/articles/PMC10064721/ /pubmed/37004120 http://dx.doi.org/10.1186/s13020-023-00740-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Cheng, Shengwen
Liu, Senrui
Chen, Bowen
Du, Chengcheng
Xiao, Pengcheng
Luo, Xuefeng
Wei, Li
Lei, Yiting
Zhao, Chen
Huang, Wei
Psoralidin inhibits osteosarcoma growth and metastasis by downregulating ITGB1 expression via the FAK and PI3K/Akt signaling pathways
title Psoralidin inhibits osteosarcoma growth and metastasis by downregulating ITGB1 expression via the FAK and PI3K/Akt signaling pathways
title_full Psoralidin inhibits osteosarcoma growth and metastasis by downregulating ITGB1 expression via the FAK and PI3K/Akt signaling pathways
title_fullStr Psoralidin inhibits osteosarcoma growth and metastasis by downregulating ITGB1 expression via the FAK and PI3K/Akt signaling pathways
title_full_unstemmed Psoralidin inhibits osteosarcoma growth and metastasis by downregulating ITGB1 expression via the FAK and PI3K/Akt signaling pathways
title_short Psoralidin inhibits osteosarcoma growth and metastasis by downregulating ITGB1 expression via the FAK and PI3K/Akt signaling pathways
title_sort psoralidin inhibits osteosarcoma growth and metastasis by downregulating itgb1 expression via the fak and pi3k/akt signaling pathways
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10064721/
https://www.ncbi.nlm.nih.gov/pubmed/37004120
http://dx.doi.org/10.1186/s13020-023-00740-w
work_keys_str_mv AT chengshengwen psoralidininhibitsosteosarcomagrowthandmetastasisbydownregulatingitgb1expressionviathefakandpi3kaktsignalingpathways
AT liusenrui psoralidininhibitsosteosarcomagrowthandmetastasisbydownregulatingitgb1expressionviathefakandpi3kaktsignalingpathways
AT chenbowen psoralidininhibitsosteosarcomagrowthandmetastasisbydownregulatingitgb1expressionviathefakandpi3kaktsignalingpathways
AT duchengcheng psoralidininhibitsosteosarcomagrowthandmetastasisbydownregulatingitgb1expressionviathefakandpi3kaktsignalingpathways
AT xiaopengcheng psoralidininhibitsosteosarcomagrowthandmetastasisbydownregulatingitgb1expressionviathefakandpi3kaktsignalingpathways
AT luoxuefeng psoralidininhibitsosteosarcomagrowthandmetastasisbydownregulatingitgb1expressionviathefakandpi3kaktsignalingpathways
AT weili psoralidininhibitsosteosarcomagrowthandmetastasisbydownregulatingitgb1expressionviathefakandpi3kaktsignalingpathways
AT leiyiting psoralidininhibitsosteosarcomagrowthandmetastasisbydownregulatingitgb1expressionviathefakandpi3kaktsignalingpathways
AT zhaochen psoralidininhibitsosteosarcomagrowthandmetastasisbydownregulatingitgb1expressionviathefakandpi3kaktsignalingpathways
AT huangwei psoralidininhibitsosteosarcomagrowthandmetastasisbydownregulatingitgb1expressionviathefakandpi3kaktsignalingpathways